Monsanto Co. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co.

MTC 2.820

+0.7%

Dec 1 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: synchro who wrote (1969)	4/22/1999 4:02:00 AM
From: JGoren	Read Replies (2) of 2539

Agree, although I responded more "legally." Price drop in sympathy with with Vioxx. FDA did not approve Vioxx for long-term pain, only acute pain; Vioxx much worse on side effects. Therefore, Vioxx at significant disadvantage to Celebrex. Merck desperately needs Vioxx to be blockbuster. Biggest worry is that, because of the disadvantage of Vioxx to Celebrex to patients, Merck will start price war in order to achieve sales. Look for nice quarterly report. I believe the report is due Friday, 4/23. Last quarter was $.05; street estimate is $.16 but whisper 2 cents below that. earningswhispers.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next